Markets
markets
Claire Yubin Oh & J. Edward Moreno

Novo Nordisk’s slide continues after CEO warns of “unprecedented pricing pressure” as outlook overshadows Q4 results

Novo Nordisk’s shares are tumbling further in premarket trading on Wednesday after CEO Mike Doustdar warned that the Danish pharma giant will face “unprecedented” price pressures in 2026, addressing the company’s annual sales forecast, which showed a decline in revenue.

“Our 2026 guidance reflects a year of unprecedented pricing pressure,” Doustdar said on a call with journalists, adding in an interview with CNBC that people should expect that US pricing “goes down before it comes back up,” as headwinds from lower US Wegovy pricing remain.

On Tuesday, NVO shares fell double digits after it forecast that sales and operating profit for 2026 will both decline by between 5% and 13% — analysts were expecting very modest growth in each.

In its 2025 annual report, released on Wednesday morning, the company detailed the disappointing guidance, citing “lower realised prices, including the MFN (‘Most Favoured Nations’) agreement in the US and the loss of exclusivity for the semaglutide molecule in certain markets in International Operations.” Novo also added that “positive impacts related to US gross-to-net sales adjustments during 2025 are not anticipated to reoccur.”

Across its actual Q4 results, things were a little rosier: sales and diluted EPS figures for Q4 2025 came in at $12.3 billion and $0.94, respectively, slightly beating analyst consensus estimates in both cases by 0.9% and 1.4% (forecasts compiled by Bloomberg).

Meanwhile, Eli Lilly reported quarterly earnings results and posted 2026 guidance on Wednesday that crushed Wall Street estimates. Indeed, though Novo was first to the GLP-1 market, Lilly is proving fierce competition, having surpassed the Danish giant’s sales by Q2 of last year. The Mounjaro maker’s earnings on Wednesday showed that the gap is only getting wider.

Just as Novo launched a new oral GLP-1 for weight loss in January — and early signs show uptake is strong — Lilly also has a weight-loss pill expected to come to market later this year. Novo is facing patent expiry for semaglutide, the active ingredient in Ozempic and Wegovy, starting this year in major markets like Canada, India, and China.

More Markets

See all Markets
markets
Max Knoblauch

United beats Q1 earnings and revenue estimates, lowers full-year profit guidance amid surging jet fuel prices

United Airlines reported its first-quarter earnings results after the bell on Tuesday. The carrier’s shares ticked down in after-hours trading.

For Q1, United reported:

  • Adjusted earnings of $1.19 per share, compared to the Wall Street estimate of $1.08 per share compiled by FactSet.

  • $14.6 billion in revenue, compared to the $14.39 billion consensus estimate.

In the first quarter, United’s fuel expense grew 12.6% from the same period last year to $3.04 billion.

For the second quarter, United expects adjusted earnings per share of between $1 and $2, shy of Wall Street expectations of $2.08. For the full year ahead, United said it expects earnings between $7 and $11 per share, compared to its prior guidance of between $12 and $14 per share.

“Guidance assumes United’s revenue recovers 40% to 50% of the fuel price increases in the second quarter, 70% to 80% of the fuel price increases in the third quarter and 85% to 100% of the fuel price increases in the fourth quarter 2026,” read the company’s investor update.

Earlier this month, United was among the first major US airlines to hike its bag fees amid higher fuel costs. Its shares have fallen more than 15% from a February high days before the war in Iran began.

United has also made waves this month following reports that CEO Scott Kirby had floated the idea of a merger with American Airlines to President Trump. A merger between two of the big four airlines would create a true US behemoth, controlling more than a third of the American market. American Air last week said it wasn’t interested in merging with United and hadn’t held talks on the idea. On Tuesday, Trump told CNBC that he doesn’t like the idea either.

Tasha Matsumoto
12h
Stocks slip as peace prospects dim

Stocks swung from positive to negative as Vice President Vance’s trip to Pakistan for Iran peace talks was canceled.

Grizzly bear growling USA.
markets
Luke Kawa

Hedge funds are following retail traders into the Magnificent 7

Hedge funds are following retail traders into the stocks the masses never stopped buying.

“As we kick off earnings for megacap tech stocks, this stood out: [hedge funds] have started buying Mag7 stocks again this month though positioning remains well below the peak levels seen in early 2016,” wrote Goldman Sachs’ Cullen Morgan.

Goldman PB Mag 7
Source: Goldman Sachs

In early April, JPMorgan strategist Arun Jain noted that retail investors had basically been selling everything but the Magnificent 7 stocks as part of a more cautious stance due to the Iran war.

(Apple has been a long-standing exception to this trend, presumably because retail traders aren’t fond of its hands-off approach to AI.)

JPM Retail flows

Last August, Jain discussed how retail activity tended to “crowd in” institutional buyers in meme stocks, while Goldman’s John Marshall advised clients to piggyback on stocks beloved by retail traders. Speculative, retail-geared assets proceeded to go on a tremendous run that soured in October.

But there are some early indications that a similar bout of speculative fervor is bubbling up once more.

markets
Luke Kawa

POET Technologies surges above $10 for first time in 4 years amid explosion in call volumes

POET Technologies is up nearly 40% this week as options market activity goes haywire in a faint echo of what got the stock on retail traders’ radars in October.

As of 11:12 a.m. ET, more than 10 calls have changed hands for every put traded. This bullish impulse has propelled the stock above the $10 threshold for the first time since March 2022.

Shares of the optical communications firm briefly dipped last week after Wolfpack Research said it was short the company because its investors would be exposed to an “IRS tax nightmare.”

The company responded that day saying it was taking measures for US shareholders that “should mitigate certain potential adverse US federal income tax consequences to it that could otherwise result from the Company’s status as a passive foreign investment company.”

Luke Kawa
17h
The parabolic surge in Avis reached new heights, with shares halted for volatility

More motivated buyers than motivated sellers.

Travelers at Sacramento International Airport (SMF)

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.
©2026 Sherwood Media, LLC